Nippon Shinyaku is engaged in the manufacture and sale of pharmaceuticals and functional food and ingredients. The Pharmaceuticals segment is engaged in the manufacture and sale of medicines to treat urological diseases, hematologic cancer, gastrointestinal diseases, allergy, inflammation, and other diseases. Co.'s main products include "Zalutia" for urinary disorder, "Vidaza" for myelodysplastic syndrome, and "Tramal" for chronic pain. The Functional Food segment manufactures and sells health food ingredients, preservatives, protein preparations and nutritional ingredients, apices and condiments. Co. is also engaged in the provision of insurance agency and real estate leasing businesses.
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.